| |
|
|
Session 72
Poster Presentations Resistance to HIV-1 Reverse Transcriptase Inhibitors Tuesday 1:30 - 3:30 pm Hall A |
| 605 | Pathways for the Emergence of Multi-dideoxynucleoside Resistant Human Immunodeficiency Virus Type 1 Variants S. Matsumi*1, P. Kosalaraksa1, S. Tsang1, M. Kavlick1, S. Harada2, H. Mitsuya1,2 1Natl Cancer Inst, Bethesda, MD and 2Kumamoto Univ Sch of Med, Japan |
| 606 | Virologic Efficacy and Patterns of Resistance Mutations in ART-naïve Patients Receiving Combination Therapy with Once-daily Emtricitabine Compared to Twice-daily Stavudine in a Randomized, Double-blind, Multi-center Clinical Trial P. Cahn*7, F. Raffi6, M. Saag5, M. Wolff4, D. Pearce3, J. M. Molina2, K. E. Borroto-Esoda1, A. L. Shaw1, J. E. Hinkle1, J. M. Waters1, E. Mondou1, J.B. Quinn1, F. S. Rousseau for the FTC-301 Study Team1 1Triangle Pharm, Inc, Durham, NC; 2Saint-Louis Hosp, Paris, France; 3St Luke Med Group, San Diego, CA; 4San-Borja Arriarian Hosp, Santiago, Chile; 5Univ of Alabama at Birmingham; 6CHU de Nantes, France; and 7Fndn HUESPED, Buenos Aires, Argentina |
| 607 | Detection of Minority Drug-resistant Variants of HIV-1 During Virologic Failure of Lamivudine, Indinavir, and Zidovudine or Stavudine in ACTG 320 C. Dykes*1, J. Najjar1, R. Bosch2, M. Wantman2, M. Furtado3, S. Hart4, S. Hammer5, L. M. Demeter1 1Univ of Rochester Sch of Med and Dentistry, NY; 2Harvard Sch of Public Hlth, Boston, MA; 3Celera Diagnostics/ABI, Foster City, CA; 4Frontier Sci, Buffalo, NY; and 5Columbia Univ, New York, NY |
| 608 | NEFA Simplification Trial: Genotypic and Phenotypic Resistance Patterns Among Patients with Virological Failure D. Dalmau*1, A. Ochoa de Echagüen1, E. Martinez2, M. Xercavins1, M. Arnedo2, JA. Arnaiz2, H. Knobel3, E. Ribera4, P. Domingo5, B. Roson6, M. Riera7, F. Segura8, JM. Llibre9, E. Pedrol10, JM. Gatell11 1Hosp Mútua de Terrassa Barcelona, Spain; 2Hosp Clin, Barcelona, Spain; 3Hosp del Mar Barcelona, Spain; 4Hosp V Hebrón, Barcelona, Spain; 5Hosp St Pau, Barcelona, Spain; 6Hosp de Bellvitge Barcelona, Spain; 7Hosp Son Dureta, Palma de Mallorca, Spain; 8Hosp Parc Taulí de Sabadell, Barcelona, Spain; 9Hosp St Jaume de Calella, Barcelona, Spain; 10Hosp Gen de Granollers, Barcelona, Spain; and 11Hosp Clin Barcelona, Spain (for the NEFA Study Team) |
| 609 | Evolution of Protease and Reverse Transcriptase Inhibitor-associated Mutations in HIV-1 Protease Inhibitor-treated Patients with Persistent Low Viremia X. Duval, S. Darmon, P. Longuet, D. Descamps, J.L. Ecobichon, S. Delarue, G. Peytavin, C. Leport, J.L. Vildé, F. Brun-Vezinet* CHU Bichat-Claude Bernard, Paris, France |
| 610 | Crystal Structures of HIV-1 Reverse Transcriptase with 4'-ethynyl-2'-deoxyfuranosyl-2,6-diaminopurine Incorporated into the Template-primer Stefan G. Sarafianos*1, Arthur D. Clark Jr.1, Gang Wang2, Barbara L. Gaffney2, Roger A. Jones2, Paul L. Boyer3, Stephen H. Hughes3, Ei-Ichi Kodama4, Hiroaki Mitsuya5, Eddy Arnold1 1Ctr for Advanced Biotechnology and Med and Rutgers Univ, Piscataway, NJ; 2Rutgers Univ, Piscataway, NJ; 3HIV Drug Resistance Prgm, NCI, NIH, Frederick, MD; 4Kyoto Univ, Japan; and 5Kumamoto Univ, Kumamoto, Japan, and NCI-NIH, Bethesda, MD |
| 611 | Structural Requirements of Nucleoside Reverse Transcriptase Inhibitors for Anti-HIV Activity Against Lamivudine-resistant Mutant YH Chong*1, RF Schinazi2, CK Chu1 1Coll of Pharmacy, Univ of Georgia, Athens, GA and 2Emory Univ Sch of Medicine/ VeteransAffairs Med Ctr, Decatur, GA |
| 612 | HIV-1 Reverse Transcriptases Resistant to Non-nucleoside Reverse Transcriptase Inhibitors Have Different Effects on the Kinetics of Single-nucleotide Incorporation R.A. Domaoal*, R.A. Bambara, L.M. Demeter Univ of Rochester, NY |
| 613 | Could Multiple Modes of Binding of a Potent NNRTI TMC125-R165335 Explain Its Potency Against Common Drug-resistant Mutants? K Das1, A D Clark1, P L Boyer2, D W Ludovici3, M-P de Béthune4, K Andries5, P Lewi*6, E Arnold1, S H Hughes2, B L De Corte3, R W Kavash3, M J Kukla3, R Pauwels4, M de Jonge6, F Daeyaert6, L Koymans6, M Vinkers6, J Heeres6, P A Janssen6 1Ctr for Advanced Biotechnology and Med and Rutgers Univ, Piscataway, NJ; 2Natl Inst of Hlth -NCI HIV Drug Resistance Prgm, Frederick, MD; 3Janssen Res Fndn, Springhouse, PA; 4Tibotec-Virco, Mechelen, Belgium; 5J&J PRD, Beerse, Belgium; and 6Ctr for Molecular Design, Vosselaar, Belgium |